Pixantrone To Be Studied In Phase I/II Trial For Aggressive Multiple Sclerosis
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that its investigational drug pixantrone will be studied in a multicenter phase I/II trial initiated by the Fondation Charcot Stichting, in Brussels, Belgium, which sponsors a consortium of centers involved in studying new therapies for the treatment for multiple sclerosis.
Sirtris Pharmaceuticals' SRT501 Slows Retinal Ganglion Cell Loss During Optic Neuritis In A Preclinical Model Of Multiple Sclerosis
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced that Kenneth Shindler, MD, PhD, University of Pennsylvania Scheie Eye Institute in Philadelphia, will present preclinical data at the North American Neuro-Ophthalmology Society annual meeting showing that SRT501, when orally administered, slows retinal ganglion cell loss during optic neuritis, a neurodegenerative eye disorder, and suppresses neurological dysfunction in a preclinical model of Multiple Sclerosis.
Pixantrone To Be Studied In Phase I/II Trial For Aggressive Multiple Sclerosis
Medical News Today Fri, 07 Mar 2008 1:08 AM PST
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that its investigational drug pixantrone will be studied in a multicenter phase I/II trial initiated by the Fondation Charcot Stichting, in Brussels, Belgium, which sponsors a consortium of centers involved in studying new therapies for the treatment for multiple sclerosis.
Health Tip: Understanding Autoimmune Diseases
HealthDay via Yahoo! News Fri, 07 Mar 2008 6:00 AM PST
(HealthDay News) -- An autoimmune disease occurs when the body's immune system mistakenly begins to attack itself. More commonly known autoimmune diseases include lupus, rheumatoid arthritis and multiple sclerosis.
The Bill criticised as 'grossly irresponsible' for making up MS drug
Daily Mail Fri, 07 Mar 2008 6:04 AM PST
Police drama The Bill has been criticised as 'grossly irresponsible' for making up the name of a drug to treat multiple sclerosis. The MS Society received calls from sufferers who wanted to know more about 'Plavitron' after it was mentioned in Wednesday night's episode of the ITV drama

CORRECTION Bayer lowers drug unit's margin target after Yasmin ...
Forbes - NY,USA
... that raising the dosage of Betaseron improved efficacy of the multiple sclerosis drug. Bayer today said it will 'consider its legal options' with regard ...
See all stories on this topic

US court rejects patent for Bayer contraceptive Yasmin
AFP -
... of its Betaferon treatment for multiple sclerosis and a complaint by the drug group Novartis against the Bayer drug Kogenate, used to treat haemophilia. ...
See all stories on this topic

New Stem Cell Technique Improves Genetic Alteration
Science Daily (press release) - USA
These scientists study spinal cord injuries, brain injuries and central nervous system diseases such as multiple sclerosis, Alzheimer’s and Huntington’s. ...
See all stories on this topic

MS Society Criticises Producers Of The Bill Over Made-up Drug, UK
The MS Society has criticised series producers of The Bill following an episode that featured an entirely made-up drug, which a storyline claimed was available for people with relapsing remitting MS.

---

Report On 547 New Medicines In Development For Neurological Disorders Released In San Antonio
The Pharmaceutical Research and Manufacturers of America (PhRMA) delivered a new report on medicines in the research pipeline for neurological diseases. The report found America's pharmaceutical research companies are testing 547 new medicines to help treat neurological diseases.